Areas of Interest
Multiple Sclerosis
Multiple sclerosis is a chronic inflammatory, demyelinating, neurodegenerative disease occurred in central nervous system that affecting about 2.5 million patients in the world. Currently existing drugs still need improvements for more efficacy and less side effects.
Cancers
According to World Health Organization (WHO), in 2022, there were about 53.5 million people worldwide who were alive within 5 years following a cancer diagnosis; in the same year, there were about 20 million new cancer cases and 9.7 million deaths. To treat this category of diseases, developing immune-modulating drugs is one of our approaches.
Alzheimer’s Disease
There were over 55 million people worldwide with dementia in 2020. The number will be reaching 78 million and 139 million in 2030 and 2050, respectively. Still no completely effective treatments exist for this disease.
Parkinson’s Disease
From the World Health Organization (WHO), the prevalence of Parkinson’s disease (PD) has globally doubled in the past 25 years with estimates in 2019 showing over 8.5 million individuals living with PD. Disability and death due to PD are increasing faster than any other neurological disorder. Current estimates suggest that, in 2019, PD resulted in 5.8 million disability-adjusted life years, an increase of 81% since 2000. It caused 329,000 deaths, an increase of over 100% since 2000. Only partially effective drugs exist for this disease.